Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01844947
Recruitment Status : Active, not recruiting
First Posted : May 3, 2013
Last Update Posted : December 29, 2017
Pierre Fabre Laboratories
Nordic Urothelial Cancer Oncology Group
Information provided by (Responsible Party):
Dr Anders Ullén, Karolinska University Hospital

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : October 2017
  Estimated Study Completion Date : April 2018